CORMEDIX INC. Deferred Revenue, Revenue Recognized
CORMEDIX INC. (CRMD) reported Deferred Revenue, Revenue Recognized of $2.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2020-03-16
- CORMEDIX INC. deferred revenue, revenue recognized for the quarter ending 2019-09-30 was $2.20K, a 0.00% change year-over-year.
- CORMEDIX INC. deferred revenue, revenue recognized for the quarter ending 2019-06-30 was $2.20K, a 0.00% change year-over-year.
- CORMEDIX INC. deferred revenue, revenue recognized for the quarter ending 2019-03-31 was $2.20K, a 0.00% change year-over-year.
- CORMEDIX INC. deferred revenue, revenue recognized for the quarter ending 2018-09-30 was $2.20K, a 93.84% decline year-over-year.
- CORMEDIX INC. deferred revenue, revenue recognized for fiscal 2019 was $2.00K, a 81.82% decline from fiscal 2018.
- CORMEDIX INC. deferred revenue, revenue recognized for fiscal 2018 was $11.00K.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2019-12-31 | $2.00K 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $2.20K 10-Q · filed 2019-11-14 | $6.60K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $2.20K 10-Q · filed 2019-08-14 | $4.40K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $2.20K 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | $11.00K 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $2.20K 10-Q · filed 2019-11-14 | $6.60K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $2.20K 10-Q · filed 2019-08-14 | $4.40K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $2.20K 10-Q · filed 2019-05-13 | |||
| 2017-09-30 | $35.70K 10-Q · filed 2017-11-09 | $101.60K 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $2.20K 10-Q · filed 2018-08-14 | $4.40K 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $2.20K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |